Literature DB >> 6971754

Determination of protease-cleaved p-aminobenzoic acid (PABA) in serum after oral administration of N-benzoyl-L-tyrosyl-p-aminobenzoic acid (PABA-peptide) in children.

G Dockter, I Nacu, E Kohlberger.   

Abstract

A modification of the urine PABA tet published by Imondi et al. is described. Ninety minutes after oral administration of PABA peptide, PABA was determined in serum. The average concentration in healthy children was 0.42 +/- 0.055 mg per 100 ml. Up to that time we recovered in the urine 66.1 +/- 6.1% of the substance previously administered. In the children with cystic fibrosis of the pancreas (CF) serum PABA concentrations were less than 0.1 mg per 100 ml. The infants under 2 months old also had clearly low serum concentrations, on average 0.29 +/- 0.06 mg per 100 ml, whereas the PABA concentrations in the older babies lay within the range for the older children (0.40 +/- 0.07 mg%).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6971754     DOI: 10.1007/BF00442103

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  14 in total

1.  Studies on the metabolism of para-aminobenzoic acid.

Authors:  C W TABOR; M V FREEMAN; J BAILY; P K SMITH
Journal:  J Pharmacol Exp Ther       Date:  1951-06       Impact factor: 4.030

2.  [Diagnosis of exocrine pancreatic malfunction with a synthetic peptide specific for chymotrypsine (author's transl)].

Authors:  W Bornschein; F L Goldmann; J Dressler
Journal:  Klin Wochenschr       Date:  1978-02-15

3.  The development of specific responses of the exocrine pancreas to pancreozymin and secretin stimulation in newborn infants.

Authors:  G Zoppi; G Andreotti; F Pajno-Ferrara; P Bellini; D Gaburro
Journal:  Pediatr Res       Date:  1973-04       Impact factor: 3.756

4.  PABA screening test for exocrine pancreatic function in infants and children.

Authors:  M Sacher; A Kobsa; D H Shmerling
Journal:  Arch Dis Child       Date:  1978-08       Impact factor: 3.791

5.  [The oral administration of N-benzoyl-L-tyrosyl-paraaminobenzoic acid (PFT) in the assessment of exocrine pancreatic function and its value within the diagnostic approach to pancreatic disease (author's transl)].

Authors:  F Fettes; K Gyr; M Singeisen; L Kayasseh; G A Stalder
Journal:  Z Gastroenterol       Date:  1978-03       Impact factor: 2.000

6.  Diagnosis of pancreatic disease by a synthetic peptide. A new test of exocrine pancreatic function.

Authors:  C Arvanitakis; N J Greenberger
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

7.  [Methodological and first clinical investigations using a new pancreatic function test].

Authors:  W Bornschein; F L Goldmann; M Otte
Journal:  Clin Chim Acta       Date:  1976-02-16       Impact factor: 3.786

8.  Oral administration of a chymotrypsin-labile peptide--a new test of exocrine pancreatic function in man (PFT).

Authors:  K Gyr; G A Stalder; I Schiffmann; C Fehr; D Vonderschmitt; H Fahrlaender
Journal:  Gut       Date:  1976-01       Impact factor: 23.059

9.  [The PABA-peptide test: a method in diagnosis of exocrine pancreatic insufficiency (author's transl)].

Authors:  E Schneiber; E Burgislaus
Journal:  Med Klin       Date:  1979-06-22

10.  Exocrine pancreatic function in protein-deficient patas monkeys studied by means of a test meal and an indirect pancreatic function test.

Authors:  K Gyr; R H Wolf; A R Imondi; O Felsenfeld
Journal:  Gastroenterology       Date:  1975-03       Impact factor: 22.682

View more
  7 in total

1.  Comparison of BT-PABA test and fecal chymotrypsin measurements in normal subjects and diabetic patients.

Authors:  G Montalto; A Carroccio; G Marino; M Soresi; C Di Marco; A Notarbartolo
Journal:  Acta Diabetol Lat       Date:  1990 Apr-Jun

2.  Value of serum PABA as a pancreatic function test.

Authors:  C Lang; K Gyr; I Tonko; D Conen; G A Stalder
Journal:  Gut       Date:  1984-05       Impact factor: 23.059

3.  Serum PABA and fluorescein in the course of Bz-Ty-PABA and pancreolauryl test as an index of exocrine pancreatic insufficiency.

Authors:  G Cavallini; W Piubello; G Brocco; R Micciolo; G Chech; G Angelini; L Benini; A Riela; L Dalle Molle; I Vantini
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

4.  Altered PABA pharmacokinetics in cystic fibrosis. Implications for bentiromide test.

Authors:  G Koren; Z Weizman; G Forstner; S M MacLeod; P R Durie
Journal:  Dig Dis Sci       Date:  1985-10       Impact factor: 3.199

5.  The usefulness of serum PABA measurement after BT-PABA administration in the diagnosis of chronic pancreatitis.

Authors:  R Myoen; T Takebe; K Ohyama
Journal:  Gastroenterol Jpn       Date:  1985-10

6.  BT-Paba test in the diagnosis of pancreatic exocrine insufficiency in cystic fibrosis: urinary and serum determinations compared.

Authors:  S Bellentani; A Grisendi; M Rinaldi; P Bertolani; G Costa; M Agostini; G Mastella; F Balli; F Manenti
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

7.  Diagnostic and therapeutic applications of bentiromide screening test for exocrine pancreatic insufficiency in patients with cystic fibrosis. Comparison with other tests of exocrine pancreatic disease.

Authors:  V S Hubbard; R O Wolf; L A Lester; A C Egge
Journal:  Dig Dis Sci       Date:  1984-10       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.